Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7799
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy ; day:29 ; month:12 ; year:2017 ; pages:1-7
Clinical and experimental nephrology ; (29.12.2017), 1-7
- Creator
-
Sakuraba, Hitoshi
- Contributor
-
Togawa, Tadayasu
Tsukimura, Takahiro
Kato, Hiroshi
SpringerLink (Online service)
- DOI
-
10.1007/s10157-017-1525-3
- URN
-
urn:nbn:de:1111-201802246671
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sakuraba, Hitoshi
- Togawa, Tadayasu
- Tsukimura, Takahiro
- Kato, Hiroshi
- SpringerLink (Online service)
Other Objects (12)
Cost-effectiveness of enzyme replacement therapy for Fabry disease
Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
Detailed characterization of anti-drug antibodies against enzyme replacement therapy in Fabry disease
Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
01.04 Non Invasive Evaluation of Arterial Remodeling in Patients with Fabry Disease after Enzyme Replacement Therapy
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
Lyso-Gb3 als Biomarker bei Morbus Fabry
Cost-effectiveness of enzyme replacement therapy for Fabry disease
Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
Detailed characterization of anti-drug antibodies against enzyme replacement therapy in Fabry disease
Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
01.04 Non Invasive Evaluation of Arterial Remodeling in Patients with Fabry Disease after Enzyme Replacement Therapy
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
Lyso-Gb3 als Biomarker bei Morbus Fabry
Cost-effectiveness of enzyme replacement therapy for Fabry disease
Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
Detailed characterization of anti-drug antibodies against enzyme replacement therapy in Fabry disease
Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease
Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
01.04 Non Invasive Evaluation of Arterial Remodeling in Patients with Fabry Disease after Enzyme Replacement Therapy
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data